Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > My thanks , philosophical thoughts

<< Previous

Bullboard Posts

Next >>

Comment by Buckhenryon Nov 23, 2024 1:57pm

43 Views

Post# 36327499

RE:RE:RE:RE:RE:My thanks , philosophical thoughts

If you read about car-t in general you will see that there are only a handful of fda approvals and the fda has a warning about using car-t. The industry is skiddish about jumping into this area. If we see good results over the next few years hopefully that will change.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario